Farallon Capital Shows DermTech Stake | Value Investing News

Farallon Capital Shows DermTech Stake

  • Per the filing, Farallon now owns 9.8% of DermTech as of August 29th with exposure to over 1.23 million shares.
  • Their stake is comprised of 615,385 shares and they also hold "Series A Preferred Shares (as defined in the Preliminary Note) convertible into an aggregate of 615,385 shares."
  • Per Yahoo Finance, DermTech is "a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States.
Rating: 
No votes yet
Article Link: 
Shared Count: 
0
Value Score: 
-5
Category: